ERBB2 and breast carcinoma: Although this study could benefit from an increased patient sample size and sufficient patient material to conduct DNA sequencing analysis, this observational cohort has nonetheless offered an insight on the wide biological spectrum within HER2+ breast carcinomas and in particular the negative association between HER2 CN intratumoral heterogeneity and patient outcome.